While institutions own 29% of NewAmsterdam Pharma Company N.V. (NASDAQ:NAMS), private equity firms are its largest shareholders with 47% ownership [Yahoo! Finance]
NewAmsterdam Pharma Company N.V. - Ordinary Shares (NAMS)
Company Research
Source: Yahoo! Finance
56% of the business is held by the top 5 shareholders Recent purchases by insiders Every investor in NewAmsterdam Pharma Company N.V. ( NASDAQ:NAMS ) should be aware of the most powerful shareholder groups. With 47% stake, private equity firms possess the maximum shares in the company. In other words, the group stands to gain the most (or lose the most) from their investment into the company. Meanwhile, institutions make up 29% of the company's shareholders. Generally speaking, as a company grows, institutions will increase their ownership. Conversely, insiders often decrease their ownership over time. Let's delve deeper into each type of owner of NewAmsterdam Pharma, beginning with the chart below. See our latest analysis for NewAmsterdam Pharma What Does The Institutional Ownership Tell Us About NewAmsterdam Pharma? Many institutions measure their performance against an index that approximates the local market. So they usually pay more attention to companies that are
Show less
Read more
Impact Snapshot
Event Time:
NAMS
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
---|---|---|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
Last Price | ||
VWAP | ||
High:
|
Max Up |
High:
|
Low:
|
Max Down |
Low:
|
%
|
Post news range |
%
|
|
Price change |
|
|
Price Change Percentage |
|
|
S&P 500 (SPX) |
|
%
|
Volume ratio |
%
|
Volume | ||
Ticks | ||
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
NAMS alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
NAMS alerts
High impacting NewAmsterdam Pharma Company N.V. - Ordinary Shares news events
Weekly update
A roundup of the hottest topics
NAMS
News
- NewAmsterdam Pharma Company N.V. (NASDAQ:NAMS) Shares Could Be 46% Below Their Intrinsic Value Estimate [Yahoo! Finance]Yahoo! Finance
- NewAmsterdam Pharma (NASDAQ: NAMS) had its "buy" rating re-affirmed by analysts at Needham & Company LLC. They now have a $36.00 price target on the stock.MarketBeat
- NewAmsterdam Pharma Provides Corporate Update and Reports Third Quarter Financial ResultsGlobeNewswire
- NewAmsterdam Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)GlobeNewswire
- NewAmsterdam Pharma to Participate in Upcoming Medical and Investor Conferences in NovemberGlobeNewswire
NAMS
Sec Filings
- 11/13/24 - Form 144
- 11/6/24 - Form 10-Q
- 11/6/24 - Form 8-K
- NAMS's page on the SEC website